Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BioGend Therapeutics Co., Ltd. (6733.TWO)
TWD25.55
+0.20 (+0.79%)
TW TWO Healthcare Biotechnology
Address
No.3-2, Park Street 115
Taipei, TW
Taipei, TW
CEO
Te-Li Chen
Website
biogend.com
IPO
2019-06-18
ISIN TW0006733009
Description
This company specializes in the development of innovative regenerative bio-orthopedic products. Its current pipeline includes BiG-001 and BiG-006, both of which are osteoinductive bone graft substitutes. Additionally, it is advancing BiG-009, an autologous cartilage repair system. Established in 2016, the firm's operations are based in Taipei, Taiwan.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
TWD25.55
+0.20 (+0.79%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
236.5K
Beta
0.09
Float Shares
67.39M
Free Float %
54.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.78% | -7.32% | -10.98% | -28.12% | -33.63% | -32.21% | -16.69% | -33.97% | -5.77% | -20.57% | -20.57% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
25.55
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
41.61
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+32.6% ★ Q1'26: +15.7% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+27.4% Q1'26: +51.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-53.8% Q1'26: -24.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-49.7% Q1'26: -36.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-44.9% Q1'26: -29.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.1% ★ Q1'26: -0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.06× Q1'26: -0.18× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
109.91M
est: 101.00M (+8.8%)
|
167.65M
est: 164.00M (+2.2%)
|
222.34M
est: 218.00M (+2.0%)
|
260.00M
260.00M – 260.00M
+19.3% YoY
|
303.00M
303.00M – 303.00M
+16.5% YoY
|
| EBITDA |
-113.94M
est: -89.76M (-26.9%)
|
-74.38M
est: -129.25M (+42.5%)
|
-110.50M
est: -171.81M (+35.7%)
|
-204.91M
-204.91M – -204.91M
-19.3% YoY
|
-238.80M
-238.80M – -238.80M
-16.5% YoY
|
| EBIT |
-168.96M
est: -95.93M (-76.1%)
|
-125.57M
est: -139.27M (+9.8%)
|
-110.50M
est: -185.12M (+40.3%)
|
-220.79M
-220.79M – -220.79M
-19.3% YoY
|
-257.31M
-257.31M – -257.31M
-16.5% YoY
|
| Net Income |
-156.33M
est: -167.38M (+6.6%)
|
-116.47M
est: -105.45M (-10.5%)
|
-95.30M
est: -79.70M (-19.6%)
|
-33.21M
-33.21M – -33.21M
+58.3% YoY
|
1.23M
1.23M – 1.23M
+103.7% YoY
|
| SGA |
95.16M
est: 781.03M (-87.8%)
|
124.04M
est: 323.08M (-61.6%)
|
—
est: 429.45M (-100.0%)
|
512.19M
512.19M – 512.19M
+19.3% YoY
|
596.90M
596.90M – 596.90M
+16.5% YoY
|
| EPS |
-1.30
est: -1.36 (+4.4%)
|
-0.95
est: -0.86 (-10.8%)
|
-0.69
est: -0.65 (-6.5%)
|
-0.27
-0.27 – -0.27
+58.3% YoY
|
0.01
0.01 – 0.01
+103.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-27.53M
OE per share TTM
-0.22
Owner's Yield
-0.86%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
38.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-3.25M
Shares Outstanding
124.70M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Te-Li Chen | Chairman & GM | 5M | — |
| Bowei Li | Senior Manager | 2M | — |
| Bozhi Zhang | Senior Manager | 2M | — |
| Guifen Zhang | Senior Manager | 2M | — |
| Shuwei Zhao | Senior Manager | 2M | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6733.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
